论文部分内容阅读
目的分析羟苯磺酸钙与福辛普利联合使用治疗糖尿病肾病的的临床疗效及不良反应。方法昆山市第三人民医院于2009年到2011年共收治糖尿病肾病患者126例,按照随机分组方法分为对照组和治疗组,对照组患者采用福辛普利进行治疗,治疗组患者在对照组治疗的基础上加服羟苯磺酸钙进行治疗,所有患者均治疗2个周期,每个周期5周,共10周。分别对患者治疗前后24 h尿白蛋白排泄率、空腹血糖、糖化血红蛋白等指标进行分析比较。结果经2个周期的治疗,与治疗前相比较,对照组和治疗组24 h尿白蛋白排泄率、糖化血红蛋白等均显著下降(P<0.05);与对照组比较,治疗后治疗组患者的24 h尿白蛋白排泄率、糖化血红蛋白显著下降(P<0.05)。对照组和治疗组患者的空腹血糖在治疗前后比较差异无统计学意义(P>0.05)。两组患者治疗期间均未出现不良反应。结论羟苯磺酸钙与福辛普利联合使用治疗糖尿病肾病临床疗效显著,安全可靠,值得临床推广使用。
Objective To analyze the clinical efficacy and side effects of calcium dobesilate and fosinopril in the treatment of diabetic nephropathy. Methods A total of 126 patients with diabetic nephropathy were admitted to the Third People’s Hospital of Kunshan City from 2009 to 2011. Patients in the control group were treated with fosinopril. The patients in the treatment group were treated in the control group On the basis of treatment plus calcium dobesilate treatment, all patients were treated 2 cycles, each cycle of 5 weeks, a total of 10 weeks. Urine albumin excretion rate, fasting blood glucose, glycosylated hemoglobin and other indicators were analyzed and compared 24 hours before and after treatment. Results After 2 cycles of treatment, the urinary albumin excretion rate and HbA1c in the control group and the treatment group decreased significantly (P <0.05) compared with those before treatment (P <0.05). Compared with the control group, the patients in the treatment group 24 h urinary albumin excretion rate, glycosylated hemoglobin decreased significantly (P <0.05). There was no significant difference in fasting blood glucose between the control group and the treatment group before and after treatment (P> 0.05). Two groups of patients during the treatment did not appear adverse reactions. Conclusion The combination of calcium dobesilate and fosinopril in the treatment of diabetic nephropathy clinical efficacy is significant, safe and reliable, it is worth promoting the use of clinical.